Divide and Conquer With Debulking in Management of Rocky Hard Cataract

June 13, 2026 updated by: Hany Mahmoud,MD, Sohag University

The management of nucleus may be challenging in rocky hard cataracts. Hard cataracts are difficult to fragment, and the excessive energy required to emulsify the hard nucleus can result in complications such as corneal edema, inflammation, wound burn, posterior capsular rupture, and zonular dialysis. different surgical techniques are used for the management of hard cataracts, with their advantages and limitations. Divide and conquer with debulking is a new technique for management of rocky hard cataract.

In this research we assess its safety comparing it with standard divide and conquer technique.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

The management of nucleus may be challenging in rocky hard cataracts. Hard cataracts are difficult to fragment, and the excessive energy required to emulsify the hard nucleus can result in complications such as corneal edema, inflammation, wound burn, posterior capsular rupture, and zonular dialysis. different surgical techniques are used for the management of hard cataracts, with their advantages and limitations. Divide and conquer with debulking is a new technique for management of rocky hard cataract.

In this research we assess its safety comparing it with standard divide and conquer technique.

Study Type

Interventional

Enrollment (Estimated)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • adults with rocky hard cataract

Exclusion Criteria:

  • patients with abnormal endothelial cell count.
  • patients with glaucoma.
  • patients with retinal problems.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: standard divide and conquer
patients with rocky hard cataract will undergo standard divide and conquer technique
phacoemulsification either by standard divide and conquer or divide and conquer with debulking.
Experimental: divide and conquer with debulking
patients with rocky hard cataract will undergo divide and conquer with debulking technique
phacoemulsification either by standard divide and conquer or divide and conquer with debulking.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
endothelial cell count
Time Frame: 3 months
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

July 1, 2026

Primary Completion (Estimated)

October 1, 2026

Study Completion (Estimated)

November 1, 2026

Study Registration Dates

First Submitted

June 13, 2026

First Submitted That Met QC Criteria

June 13, 2026

First Posted (Actual)

June 17, 2026

Study Record Updates

Last Update Posted (Actual)

June 17, 2026

Last Update Submitted That Met QC Criteria

June 13, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • Soh-Med-26-5-3PD

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Sharing Time Frame

after study completion

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cataract Mature

Clinical Trials on cataract operation by phacoemulsification

3
Subscribe